Terns Pharmaceuticals, Inc. (TERN): Price and Financial Metrics
TERN Price/Volume Stats
| Current price | $4.56 | 52-week high | $14.04 |
| Prev. close | $4.59 | 52-week low | $3.26 |
| Day low | $4.32 | Volume | 866,400 |
| Day high | $4.65 | Avg. volume | 873,311 |
| 50-day MA | $6.61 | Dividend yield | N/A |
| 200-day MA | $5.98 | Market Cap | 294.81M |
TERN Stock Price Chart Interactive Chart >
Terns Pharmaceuticals, Inc. (TERN) Company Bio
Terns Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company discovers and develops molecularly-targeted and oral molecule drugs for the treatment of liver disease and cancer. Terns Pharmaceuticals serves customers worldwide.
Latest TERN News From Around the Web
Below are the latest news stories about TERNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TERN as an investment opportunity.
Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology SummitFOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that members of management will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit. Details are as follows: JMP Securi |
Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive OfficerFOSTER CITY, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious oncologic and metabolic diseases, today announced that Senthil Sundaram, the Company’s recently retired Chief Executive Officer, passed away on November 22, 2023, following his battle with cancer. “It is with great sadness we announce Sen’s passing. Se |
Terns Pharmaceuticals Inc (TERN) Reports Q3 2023 Financials and Corporate ProgressAdvancements in Clinical Trials and Strong Cash Position Highlighted |
Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate UpdatesAnnounced global Phase 1 clinical trial design of TERN-701 (allosteric BCR-ABL) for CML with patient screening anticipated in December 2023 and interim top-line data expected in the second half of 2024 Dosed first participant in Phase 1 clinical trial of TERN-601 (oral GLP-1) for obesity with top-line data expected in the second half of 2024 Reported positive top-line data from Phase 2a DUET clinical trial that demonstrated TERN-501 (THR-β) has best-in-class potential based on overall profile of |
Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023TERN-501 treatment over 12 weeks significantly improved liver fat content and fibro-inflammation in NASH patients, with low rates of gastrointestinal and no cardiovascular adverse events TERN-501 significantly increased SHBG, a marker of target engagement and predictor of histologic response in the THR-β class Company to host in-person investor event following late-breaking data today at 4:00 p.m. ET in Boston FOSTER CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“T |
TERN Price Returns
| 1-mo | -30.38% |
| 3-mo | -6.17% |
| 6-mo | -17.84% |
| 1-year | -65.58% |
| 3-year | -74.83% |
| 5-year | N/A |
| YTD | -29.74% |
| 2023 | -36.25% |
| 2022 | 43.99% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...